PubMed Health⌕ Search

PubMed · 12723749

Ibuprofen overdose.

Abstract

Enquiries about the management of patients possibly suffering from ibuprofen overdose account for over 5% of the total enquiry workload of the London Centre of the United Kingdom National Poisons Information Service. Unlike overdose with aspirin and paracetamol, no additional pathophysiological findings have been reported in ibuprofen overdose and all the demonstrated toxic effects relate to its known pharmacological actions and the effects of accumulation of the two acidic metabolites, 2-hydroxyibuprofen and 2-carboxylibuprofen. The most striking finding in reported cases is that the great majority of patients suffer no or only mild symptoms. In one series of 1,033 enquiries involving ingestion of ibuprofen alone, 705 (65%) patients were asymptomatic; 199 (18%) experienced mild symptoms; and 23 (2%) experienced moderate symptoms. We are aware of only seven case reports of fatal overdose with ibuprofen and in each case there are complicating factors related to other drugs and/or other disease processes. The management of ibuprofen overdose is generally straightforward and can be related to the dose ingested. Initial findings suggest even less evidence for toxicity associated with modified release formulations than with the conventional tablets. There is at present no reason to be concerned that co-ingestion of ethanol increases the risk of toxicity from ibuprofen overdose. Ibuprofen overdose is common but serious toxic effects are unusual and guidelines for treatment are straightforward.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Glyn Volans, Jane Monaghan, Mark Colbridge. 2003. Ibuprofen overdose.. https://pubmed.ncbi.nlm.nih.gov/12723749/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Nitrosulindac (NCX 1102): a new nitric oxide-donating non-steroidal anti-inflammatory drug (NO-NSAID), inhibits proliferation and induces apoptosis in human prostatic epithelial cell lines.

BACKGROUND: The aim of our study was to explore the anti-tumoral potential of the Nitric Oxide-Donating Non-Steroidal Anti-Inflammatory Drugs (NO-NSAID) NCX1102 (nitrosulindac), on three human prostatic epithelial cell lines at varying degree of transformation (PNT1A, LNCaP, and PC3). METHODS: Cytotoxicity, anti-proliferative effects, cell-cycle alterations, morphological changes, and apoptosis were investigated after treatment with nitrosulindac in comparison to the native molecule sulindac. Involvement of the polyamine pathway in the action of nitrosulindac was also examined. RESULTS: Nitrosulindac but not sulindac exerted a cytotoxic effect on all cell lines and an anti-proliferative effect on LNCaP and PC3 cells only. Nitrosulindac differentially altered the cell cycle, induced mitotic arrest and displayed a pro-apoptotic activity in all cell lines. Finally, the polyamine pathway does not seem to be involved in the mechanism of nitrosulindac action. CONCLUSIONS: Our results demonstrate the anti-proliferative and proapoptotic activity of nitrosulindac on prostate cancer cell lines and suggest its potential interest for new strategies in the management of prostate cancer.

Anti-Inflammatory Agents, Non-Steroidal↗

Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: protocol of a randomized controlled trial [ISRCTN43532635].

BACKGROUND: Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are a widely used class of therapy in the treatment of chronic pain and inflammation. The drugs are effective and can be relatively inexpensive thanks to available generic versions. Unfortunately the traditional NSAIDs are associated with gastrointestinal complications in a small proportion of patients, requiring costly co-therapy with gastro-protective agents. Recently, a new class of non-steroidal anti-inflammatory agents known as coxibs has become available, fashioned to be safer than the traditional NSAIDs but priced considerably higher than the traditional generics. To help physicians choose appropriately and cost-effectively from the expanded number of anti-inflammatory therapies, scientific bodies have issued clinical practice guidelines and third party payers have published restricted reimbursement policies. The objective of this study is to determine whether an educational intervention can prompt physicians to adjust their prescribing in accordance with these expert recommendations. METHODS: This is an ongoing, randomized controlled trial. All primary care physicians in Manitoba, Canada have been randomly assigned to a control group or an intervention study group. The educational intervention being evaluated consists of an audit and feedback mechanism combined with optional participation in a Continuing Medical Education interactive workshop. The primary outcome of the study is the change, from pre-to post-intervention, in physicians' appropriate prescribing of non-steroidal anti-inflammatory therapies for patients requiring chronic treatment. Three classes of non-steroidal anti-inflammatory therapies have been identified: coxib therapy, traditional NSAID monotherapy, and traditional NSAID therapy combined with gastro-protective agents. Appropriate prescribing is defined based on international clinical practice guidelines and the provincial drug reimbursement policy in Manitoba.

Anti-Inflammatory Agents, Non-Steroidal↗